Thakur Raghu Raj Singh
Overview
Explore the profile of Thakur Raghu Raj Singh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Annuryanti F, Adhami M, Abdi U, Robles J, Larraneta E, Vora L, et al.
Int J Pharm
. 2024 Dec;
669():125099.
PMID: 39706380
Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are the primary causes of vision impairment and blindness worldwide. The current treatment for these diseases is an intravitreal injection of anti-VEGF...
2.
Desai N, Pande S, Salave S, Raghu Raj Singh T, Vora L
Drug Discov Today
. 2024 Jun;
29(8):104060.
PMID: 38866357
The application of nanotechnology has significantly advanced the development of novel platforms that enhance disease treatment and diagnosis. A key innovation in this field is the creation of antitoxin nanoparticles...
3.
Desai N, Chavda V, Raghu Raj Singh T, Thorat N, Vora L
Small
. 2024 May;
20(35):e2401631.
PMID: 38693099
Cancer nanovaccines represent a promising frontier in cancer immunotherapy, utilizing nanotechnology to augment traditional vaccine efficacy. This review comprehensively examines the current state-of-the-art in cancer nanovaccine development, elucidating innovative strategies...
4.
Farooq U, OReilly N, Ahmed Z, Gasco P, Raghu Raj Singh T, Behl G, et al.
Int J Pharm
. 2024 Mar;
654:123958.
PMID: 38442797
Clinicians face numerous challenges when delivering medications to the eyes topically because of physiological barriers, that can inhibit the complete dose from getting to the intended location. Due to their...
5.
Zhang C, Jahan S, Zhang J, Bianchi M, Volpe-Zanutto F, Baviskar S, et al.
Int J Pharm
. 2023 Nov;
648:123585.
PMID: 37952560
It is estimated that nearly a half of the world's population over 30 years old suffer from some kind of periodontal disease (PD). Although preventable, PD can pose a significant...
6.
Glover K, Mishra D, Gade S, Vora L, Wu Y, Paredes A, et al.
Adv Drug Deliv Rev
. 2023 Sep;
201:115082.
PMID: 37678648
In the field of ocular drug delivery, topical delivery remains the most common treatment option for managing anterior segment diseases, whileintraocular injectionsare the current gold standard treatment option for treating...
7.
Mishra D, Gade S, Pathak V, Vora L, McLoughlin K, Medina R, et al.
Drug Discov Today
. 2023 Jun;
28(9):103676.
PMID: 37343817
The constraints of delivering conventional drugs, biologics and cell-based therapeutics to target ocular sites necessitate the fabrication of novel drug delivery systems to treat diverse ocular diseases. Conventional ocular drug...
8.
Mishra D, Gade S, Glover K, Sheshala R, Raghu Raj Singh T
Curr Eye Res
. 2022 Aug;
48(2):208-218.
PMID: 36036478
Intravitreal administration of drug molecules is one of the most common routes for treating posterior segment eye diseases. However, the properties of vitreous humour changes with the time. A number...
9.
Wu Y, Vora L, Mishra D, Adrianto M, Gade S, Paredes A, et al.
Biomater Adv
. 2022 Aug;
137:212767.
PMID: 35929230
Intravitreal injections (IVT) are regarded as the gold standard for effective delivery of hydrophobic drugs to the back of the eye. However, as a highly invasive procedure, the injection itself...
10.
Wu Y, Vora L, Donnelly R, Raghu Raj Singh T
Drug Deliv Transl Res
. 2022 Jun;
13(8):2142-2158.
PMID: 35713782
The discovery of proteins that neutralise vascular endothelial growth factors, such as pegaptanib, ranibizumab and aflibercept, can inhibit the process of angiogenesis, thereby restoring eyesight in individuals with retinal vascular...